Changeflow GovPing Pharma & Drug Safety Nanoparticle Wound Healing Treatment Patent US1...
Routine Rule Added Final

Nanoparticle Wound Healing Treatment Patent US12599698B2

Favicon for changeflow.com USPTO Patent Grants - Pharma (A61K)
Published
Detected
Email

Summary

USPTO granted patent US12599698B2 to Kismet Technologies Inc. on April 14, 2026, covering a therapeutic article with metal-modified cerium oxide nanoparticles (mCNPs) for wound healing and antimicrobial infection control. The patent includes 19 claims for the nanoparticle-treated fiber composition with particles sized 3-35nm.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

USPTO granted patent US12599698B2 to Kismet Technologies Inc. for a therapeutic article comprising fibers treated with metal-modified cerium oxide nanoparticles (mCNPs) sized 3-35nm, mixed at 0.01-0.1 weight percentage with polymeric binder, dispersant, and/or stabilizer. The patent covers wound healing applications and antimicrobial infection control barriers.

The grant provides Kismet Technologies Inc. with exclusive IP rights to this nanoparticle wound treatment technology in the US market. Competitors developing similar nanoparticle wound healing products will need to either license the technology or design around the patent claims.

Archived snapshot

Apr 17, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Therapeutic article of manufacture with nanoparticles to promote wound healing and/or antimicrobial infection control

Grant US12599698B2 Kind: B2 Apr 14, 2026

Assignee

Kismet Technologies Inc.

Inventors

Christina H. Drake

Abstract

A therapeutic article of manufacture that includes a body having fibers treated with a mixture including metal-modified cerium oxide nanoparticles (mCNPs) and one or more of a polymeric binder, a dispersant and a stabilizer. The mCNPs have a predominant 3+ surface charge and in a range of about 3-35 nanometers (nm) in size. The mCNPs are mixed in an amount that is in a range of about 0.01 to 0.1 weight percentage of the mixture having the mCNPs and the one or more of a polymeric binder, a dispersant and a stabilizer. The metal (m) is an antimicrobial promoting metal that is non-ionizing. A method is also provided that promotes wound healing and/or antimicrobial infection control with a barrier of the therapeutic article of manufacture.

CPC Classifications

A61K 33/00 A61K 9/14 A61K 9/0014 B82Y 30/00

Filing Date

2022-10-26

Application No.

17973769

Claims

19

View original document →

Get daily alerts for USPTO Patent Grants - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 14th, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12599698B2

Who this affects

Applies to
Manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent grants IP licensing
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Medical Devices

Get alerts for this source

We'll email you when USPTO Patent Grants - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!